

Air pollution and lung health among people with HIV

Crystal M. North, MD MPH

Pulmonary and Critical Care Medicine, Massachusetts General Hospital

Assistant Professor of Medicine, Harvard Medical School

Department Associate, Environmental Health, Harvard T.H. Chan School of Public Health




Outline

- Why HIV and lung disease, and why sub-Saharan Africa?
- 3 Research Questions:
 1. *What is the prevalence of lung dysfunction among PWH in sub-Saharan Africa?*
 2. *What is ambient air quality in rural Uganda?*
 3. *Do people with HIV have higher risk of air pollution-associated lung disease?*
- Ongoing work/next steps

Outline


- Why HIV and lung disease, and why sub-Saharan Africa?
- 3 Research Questions:
 1. *What is the prevalence of lung dysfunction among PWH in sub-Saharan Africa?*
 2. *What is ambient air quality in rural Uganda?*
 3. *Do people with HIV have higher risk of air pollution-associated lung disease?*
- Ongoing work/next steps



Globally, ~ 3.9 million deaths/year from chronic respiratory diseases


More than HIV/AIDS, TB and malaria combined

80% of lung disease morbidity and mortality occurs in low- and middle-income countries




Smoking might not be the leading cause of lung disease in sub-Saharan Africa (...for now)


Figure 4. Trends in current tobacco use among people aged ≥ 15 years




cigarettes smoked per person per year (2016)



Global *deaths* from chronic lung disease




Global *causes* of chronic lung disease




In sub-Saharan Africa, HIV may be an underappreciated driver of chronic lung disease

People with
HIV are at risk
for chronic lung
disease




With ART, the epidemiology of lung disease among PWH has changed




Smoking and HIV

- Smoking is more prevalent among PWH
- However, despite similar smoking levels, PWH have:
 - Accelerated emphysematous lung destruction
 - More COPD
 - More lung cancer
- For PWH on ART, smoking reduces life expectancy more than HIV itself




34 years old, 16 pack-years



30 years old, 9 pack-years


Smoking and HIV

HIV+ smokers exhibit more lung damage than HIV- smokers




HIV itself causes direct lung injury


Innate Immunity



Adaptive Immunity




People with HIV are at risk for chronic lung disease



Most of what we know about HIV and lung disease is from high income settings

Most people with HIV live in sub-Saharan Africa


- Globally, 38 million people are living with HIV
- Sub-Saharan Africa is the epicenter
 - 2/3 of global population with HIV
 - 50% of new HIV diagnoses
- Non-communicable diseases are leading causes of morbidity and mortality among people with HIV on ART
- Lung disease risk factors (e.g., smoking, tuberculosis, air pollution) differ in SSA



Most people with HIV in SSA are women and girls

Share of women among the population living with HIV, 2019

Data is based on adults aged 15 years and older.




- 2/3 of new HIV diagnoses in SSA are among women and girls
- Data on lung disease among PLWH are from high income countries, where most PWH are men
- Many other lung diseases exhibit sex/gender differences, including COPD

Outline

- Why HIV and lung disease, and why sub-Saharan Africa?
- 3 Research Questions:
 1. *What is the prevalence of lung dysfunction among PWH in sub-Saharan Africa?*
 2. *What is ambient air quality in rural Uganda?*
 3. *Do people with HIV have higher risk of air pollution-associated lung disease?*
- Ongoing work/next steps

Where We Work: Mbarara, Uganda




The Study Cohort

- Age ≥ 40 years (n ~ 300)
- Two sub-groups:
 - HIV+ : In care, on ART ≥ 3 years
 - HIV - : Age/gender similar
- Since 2015, annual:
 - Respiratory symptom questionnaire
 - Pulmonary function testing
 - Personal air pollution measures
 - Blood samples
 - (recently) Induced sputum samples



Measuring Lung Function: Pulmonary Function Testing (spirometry)



Post-bronchodilator $FEV_1/FVC < 0.7 = COPD$

Figure 1. Study participants, 2015 through 2018




Table 1. Baseline Characteristics

	Total Cohort (n = 278)	HIV + (n = 145)	HIV - (n = 133)	<i>p</i> value
Demographics				
Age	52 [48, 55]	52 [49, 55]	52 [48, 55]	0.35
Women	130 (47)	68 (47)	62 (47)	0.96
Smoking history				0.004
Current	41 (15)	12 (8)	29 (22)	
Former	95 (34)	50 (34)	45 (34)	
Never	142 (51)	83 (57)	59 (44)	
Prior tuberculosis	17 (6)	17 (12)	0 (0)	< 0.001
Prior pneumonia	24 (9)	17 (12)	7 (5)	0.06
Biomass exposure				< 0.001
Charcoal	40 (14)	39 (27)	1 (1)	
Firewood	236 (86)	104 (73)	132 (99)	
HIV Characteristics				
Viral Load, copies/μL				
Undetectable		135 (94)		
Detectable, ≤ 10,000		6 (4)		
Detectable, > 10,000		2 (1)		
CD4 count, cells/mm ³				
100 – 349		26 (18)		
350 – 499		55 (38)		
≥ 500		64 (44)		
ART duration		9 [8, 10]		

Most COPD diagnoses were among PWH

Table 2 Description of lung function and cardiovascular disease across cohort

Disease measure	Total cohort (n = 265)	HIV+ (n = 140)	HIV– (n = 125)	<i>p</i> value*
FEV ₁ (L)	2.47 (2.07, 2.95)	2.40 (2.08, 2.95)	2.52 (2.04, 2.95)	0.853
FVC (L)	3.14 (2.66, 3.70)	3.09 (2.67, 3.76)	3.24 (2.66, 3.68)	0.936
FEV ₁ /FVC	0.80 (0.76, 0.83)	0.8 (0.75, 0.83)	0.8 (0.77, 0.83)	0.671
COPD (FEV ₁ /FVC < 0.7)	17 (6%)	13 (9%)	4 (3%)	0.044



Systemic inflammation is associated with ↓ lung function among PWH

Table 1: Associations between lung function (mL) and serum biomarkers

	HIV+ (n=122 [†])		HIV- (n=108 [†])	
	FEV ₁	FVC	FEV ₁	FVC
IL-6, per IQR increase	-18.1 (-29.1 to -7.1)**	-17.1 (-28.2 to -5.9)**	-6.2 (-16.0 – 3.5)	-8.7 (-20.8 – 3.5)
sCD14, per IQR increase	2.3 (-11.7 – 16.3)	7.0 (-6.9 – 21.0)	6.2 (-4.3 – 16.6)	8.9 (-4.1 – 21.8)
sCD163, per IQR increase	-11.4 (-24.0 – 1.2)	-14.3 (-26.9 to -1.7)*	-3.7 (-13.8 – 6.3)	-6.5 (-19.0 – 6.1)
hsCRP, >3mg/L vs. <1mg/L	-39.3 (-61.7 to -16.9)**	-44.0 (-48.4 to -6.4)***	-37.9 (-63.2 to -12.6)**	-58.0 (-88.4 to -27.5)***

*p < 0.05, **p < 0.01, ***p<0.001; † hsCRP model sample sizes: n=120 (HIV+) & n=107 (HIV-); ‡ p values for HIV*biomarker interaction terms

HIV serostatus is associated with faster lung function decline among women (but not men)




Why? 3 Working Hypotheses


Differences in:

1. Air pollution exposure and/or influence on lung health
2. HIV-associated systemic inflammation
3. Advanced reproductive aging

Are women with HIV just exposed to more air pollution? Maybe.




Example of ambulatory carbon monoxide levels over time




Are women with HIV just exposed to more air pollution? Maybe.

Ambulatory carbon monoxide exposure is highest in women with HIV




Ambulatory PM_{2.5} exposure is not different by sex or HIV serostatus




Outline

- Why HIV and lung disease, and why sub-Saharan Africa?
- 3 Research Questions:
 1. *What is the prevalence of lung dysfunction among PWH in sub-Saharan Africa?*
 2. *What is ambient air quality in rural Uganda?*
 3. *Do people with HIV have higher risk of air pollution-associated lung disease?*
- Ongoing work/next steps


Ambient air pollution: Particulate matter (PM)



PM_{2.5} Source Contributions





Percentage of global deaths from specific causes attributable to total air pollution



Ambient air quality is poor across SSA, but data are sparse


Annual PM_{2.5} Levels



Source Data






Air pollution monitoring stations



Data updated Tue December 13, 2022





Ambient PM_{2.5} levels in Mbarara



2006 Air quality standard

2021 Air quality standard


Ambient PM_{2.5} sources in Mbarara



Outline

- Why HIV and lung disease, and why sub-Saharan Africa?
- 3 Research Questions:
 1. *What is the prevalence of lung dysfunction among PWH in sub-Saharan Africa?*
 2. *What is ambient air quality in rural Uganda?*
 3. *Do people with HIV have higher risk of air pollution-associated lung disease?*
- Ongoing work/next steps

Among PWH, does air pollution act like smoking?



At similar air pollution exposure levels, people with HIV have ↑ odds of resp symptoms


Table 6 Correlates of self-reported respiratory symptoms, stratified by HIV serostatus

Characteristic	HIV Positive (202 sampling periods)		HIV Negative (218 sampling periods)	
	Adjusted OR	95% CI	Adjusted OR	95% CI
Female sex	1.9	0.8, 4.3	11.2***	3.3, 38.0
1-h CO > 35 ppm	2.5*	1.0, 6.0	1.4	0.1, 14.4
Smoking status				
Current	2.6	0.6, 11.3	0.9	0.1, 5.0
Former	0.8	0.3, 2.0	1.3	0.6, 3.2

Outline

- Why HIV and lung disease, and why sub-Saharan Africa?
- 3 Research Questions:
 1. *What is the prevalence of lung dysfunction among PWH in sub-Saharan Africa?*
 2. *What is ambient air quality in rural Uganda?*
 3. *Do people with HIV have higher risk of air pollution-associated lung disease?*
- Ongoing work/next steps

Work in Progress – LUNG Study



Work in Progress – Air Quality Study




Figure 1. Regional map of UGANDAC and HopeNet participants' home locations (blue dots), the Mbarara Ambient Air Sampler (black triangle), and the four additional ambient air sampling sites (red triangles) to be established with Burke Fellowship funds.








Figure 3. PM_{2.5} concentrations as estimated by the NASA GEOS model (red) compare well to corresponding observations at the Mbarara Ambient Air Sampler (blue) from May 2018 through Feb 2019. (Figure courtesy of C. Keller, NASA)



Ongoing Work and Next Steps



Questions?

cnorth@mgh.harvard.edu